Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial (2020)
https://pubmed.ncbi.nlm.nih.gov/31813637/

The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis (2019)
https://pubmed.ncbi.nlm.nih.gov/31551538/

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial (2019)
https://pubmed.ncbi.nlm.nih.gov31732180/

Axial spondyloarthritis (2017)
https://pubmed.ncbi.nlm.nih.gov/28110981/